CHANGES IN ELF SCORE DURING TREATMENT WITH PEGYLATED INTERFERON AND SILYMARIN ARE ASSOCIATED WITH PROGRESSION OF HISTOLOGICAL LIVER DISEASE IN NON-RESPONDER PATIENTS WITH HEPATITIS C

被引：0
|
作者：
Tanwar, S. [1 ]
Ellis, E. [2 ]
Parkes, J. [2 ]
Herold, C. [3 ]
Rosenberg, W. [1 ]
机构：
[1] UCL, Ctr Hepatol, London, England
[2] Univ Southampton, Southampton, Hants, England
[3] Univ Erlangen Nurnberg, Erlangen, Germany
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60127-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
125
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [31] Gene expression biomarkers predicting response to pegylated interferon alpha (PEG-IFN) and ribavirin (RBV) in the peripheral blood of patients with chronic hepatitis C (CH-C), non-responder (NR) to previous treatment
    Younossi, Zobair M.
    Collantes, Rochelle
    Baranova, Ancha
    Kim, Amy
    Manyam, Ganiraju
    Stepanova, Maria
    Santini, Chris
    Sigua, Chris
    Chan, Joanne
    Iverson, Ayuko
    Chang, Sheng-Yung
    HEPATOLOGY, 2007, 46 (04) : 389A - 389A
  • [32] Dynamics of viral quasispecies during interferon therapy in non responder chronic hepatitis C patients
    Thelu, MA
    Baud, M
    Leroy, V
    Seigneurin, JM
    Zarski, JP
    JOURNAL OF CLINICAL VIROLOGY, 2001, 22 (01) : 125 - 131
  • [33] Long-term administration of interferon-α in non-responder patients with chronic hepatitis C:: follow-up of liver fibrosis over 5 years
    Guerret, S
    Desmoulière, A
    Chossegros, P
    Costa, AMA
    Badid, C
    Trépo, C
    Grimaud, JA
    Chevallier, M
    JOURNAL OF VIRAL HEPATITIS, 1999, 6 (02) : 125 - 133
  • [34] Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study
    Cornberg, M
    Hadem, J
    Herrmann, E
    Schuppert, F
    Schmidt, HHJ
    Reiser, M
    Marschal, O
    Steffen, M
    Manns, MP
    Wedemeyer, H
    JOURNAL OF HEPATOLOGY, 2006, 44 (02) : 291 - 301
  • [35] Natural histological progression of liver disease in patients with hepatitis C after liver transplantation.
    Araya, V
    Vinayek, R
    Aleong, R
    Lee, R
    Vargas, H
    Lombardero, M
    Laskus, T
    Wang, L
    Dodson, F
    Fung, J
    Rakela, J
    HEPATOLOGY, 1997, 26 (04) : 104 - 104
  • [36] The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-α and ribavirin combined therapy for chronic hepatitis C patients
    Chen, P. -J.
    Hwang, Y.
    Lin, C. G. -J.
    Wu, Y. -J.
    Wu, L. S. -H.
    INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2008, 35 (02) : 153 - 157
  • [37] Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin.
    Samuel, D
    HEPATOLOGY, 2003, 38 (04) : 531A - 531A
  • [38] Interferon plus ribavirin in interferon non-responder or relapsing chronic hepatitis C patients:: End of treatment response and sustained response at third follow-up month.
    Moreno-Monteagudo, JA
    García-Buey, L
    Fernández-Bermejo, M
    Sanz, P
    Borque, MJ
    Lo Iacono, O
    García-Monzón, C
    Moreno-Otero, R
    HEPATOLOGY, 1998, 28 (04) : 476A - 476A
  • [39] Celiac disease manifested during the treatment of chronic hepatitis C by pegylated alpha interferon and ribavirin
    Gombosova, L.
    Jarcuska, P.
    Benova, B.
    Benicky, M.
    Lazurova, I
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2011, 112 (06): : 360 - 362
  • [40] Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: A case report
    Tomasiewicz, K
    Modrzewska, R
    Semczuk, G
    ADVANCES IN THERAPY, 2006, 23 (01) : 139 - 142
12345